Haleon plc: EMTN programme - Publication of listing particulars

7 May 2026: Haleon plc (the "Company" or "Haleon") announces that, following a routine annual update, listing particulars dated 7 May 2026 regarding Haleon UK Capital plc's and Haleon Netherlands Capital B.V.'s £10,000,000,000 Euro Medium Term Note ("EMTN") Programme, guaranteed by the Company, have been published (the "Listing Particulars").

A copy of the Listing Particulars is available for inspection and can be downloaded from www.haleon.com/investors/debt-investors.

Amanda Mellor 

Company Secretary 

Enquiries

About Haleon

Haleon (LSE/NYSE: HLN) is a consumer company that is solely focused on better everyday health. Our people, our brands, our research, our investment and our innovation are aimed at improving the everyday health of consumers. Our product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Our superior brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are trusted by more than one billion consumers and are recommended by health professionals around the world.

For more information, please visit www.haleon.com. 

Disclaimer

Please note that the information contained in the Listing Particulars may be addressed to and/or targeted at persons who are residents of particular countries (specified in the Listing Particulars) only and is not intended for use and should not be relied upon by any person outside these countries and/or to whom the offer contained in the Listing Particulars is not addressed. Prior to relying on the information contained in the Listing Particulars, you must ascertain from the Listing Particulars whether or not you are part of the intended addressees of the information contained in the Listing Particulars.

Your right to access this service is conditional upon complying with the above requirement.